F. M. Hoffman
Papers
1
Total Citations
22
H-Index
1
About
F. M. Hoffman is a leading figure in drug metabolism and toxicology, with a primary focus on the development of high-throughput screening (HTS) assays for evaluating drug safety and interactions. Their most impactful work, the 2007 paper "High Throughput Screening Assay for UDP-Glucuronosyltransferase 1A1 Glucuronidation Profiling," has garnered 22 citations and established a critical methodology for assessing compound toxicity and drug-drug interactions early in the drug development pipeline. By enabling rapid profiling of UDP-glucuronosyltransferase 1A1 (UGT1A1) activity—a key enzyme in drug clearance and toxicity—Hoffman’s assay has helped reduce costs and improve the safety of drug candidates. This contribution is particularly notable for addressing the challenges of predicting adverse reactions, such as hyperbilirubinemia, associated with UGT1A1 inhibition. Hoffman’s work underscores the importance of integrating metabolism studies into preclinical screening, making their research essential for pharmaceutical scientists and toxicologists aiming to streamline drug development while minimizing patient risk. Their innovative approach continues to influence the design of safer therapeutics.
Research Focus
Key Achievements
Top Papers
- 1